Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Experts are expecting strong results driven by the strong demand of Lilly's blockbuster medications, particularly its insulin portfolio. However, there are also concerns about potential pressures from rising cost